🇺🇸 FDA
Pipeline program

CHF6001 DPI

CLI-06001AC1-01

Phase 2 small_molecule active

Quick answer

CHF6001 DPI for Asthma is a Phase 2 program (small_molecule) at Chiesi Farmaceutici S.p.A with 1 ClinicalTrials.gov record(s).

Program details

Company
Chiesi Farmaceutici S.p.A
Indication
Asthma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials